← Browse by Condition
Medical Condition

systemic sclerosis ssc

Total Trials
9
Recruiting Now
9
Trial Phases
Phase 2, Phase 1
NCT06991114 Phase 2
Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Enrollment
90 pts
Location
United States, Bulga...
Sponsor
Artiva Biotherapeutics, Inc.
View Trial →
NCT06672822 Phase 2
Recruiting

Intralesional Injection of STS in Treatment of Calcinosis

Enrollment
20 pts
Location
United States
Sponsor
Robyn T. Domsic, MD, MPH
View Trial →
NCT07292961
Recruiting

Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma

Enrollment
48 pts
Location
Turkey (Türkiye)
Sponsor
Hacettepe University
View Trial →
NCT06865118
Recruiting

Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis

Enrollment
20 pts
Location
Norway
Sponsor
Oslo University Hospital
View Trial →
NCT07413341 Phase 1
Recruiting

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Enrollment
12 pts
Location
China
Sponsor
Therorna
View Trial →
NCT07184450 Phase 1
Recruiting

Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases

Enrollment
11 pts
Location
China
Sponsor
Chongqing Precision Biotech Co...
View Trial →
NCT06794008 Phase 2
Recruiting

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Enrollment
50 pts
Location
China
Sponsor
Peking University People's Hos...
View Trial →
NCT06642870
Recruiting

Rare AutoImmune SElf-management Programme Development

Enrollment
360 pts
Location
United Kingdom
Sponsor
University of the West of Engl...
View Trial →
NCT07167537 Phase 1
Recruiting

A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases

Enrollment
44 pts
Location
China
Sponsor
Beijing GoBroad Hospital
View Trial →